Division

United Kingdom

F1NB : Viruses have been listed according to their order (O), family (F) and genus (G).

Annotations

F1: Substituted by Commission Directive (EU) 2019/1833 of 24 October 2019 amending Annexes I, III, V and VI to Directive 2000/54/EC of the European Parliament and of the Council as regards purely technical adjustments.

F2: Inserted by Commission Directive (EU) 2020/739 of 3 June 2020 amending Annex III to Directive 2000/54/EC of the European Parliament and of the Council as regards the inclusion of SARS-CoV-2 in the list of biological agents known to infect humans and amending Commission Directive (EU) 2019/1833.

f1: See paragraph 8 of the introductory notes.
f2: In line with Article 16(1)(c), non-propagative diagnostic laboratory work involving SARS-CoV-2 should be conducted at a facility using procedures equivalent to at least containment level 2. Propagative work involving SARS-CoV-2 should be conducted at a containment level 3 laboratory with air pressure negative to atmosphere.
f3: Classification according to WHO Global Action Plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use.
f4: Tick-borne encephalitis.
f5: Only for types A and B.
f6: Recommended for work involving direct contact with these agents.
f7: Two viruses are identified: one a buffalopox type and the other a variant of the Vaccinia virus.
f8: Variant of cowpox virus.
f9: Variant of Vaccinia.
f10: At present there is no evidence of disease in humans caused by the other retroviruses of simian origin. As a precaution containment level 3 is recommended for work with them.
f11: Hepatitis delta virus is pathogenic in workers only in the presence of simultaneous or secondary infection caused by hepatitis B virus. Vaccination against hepatitis B virus will therefore protect workers who are not affected by hepatitis B virus against hepatitis delta virus.